

TRIAL TO INCREASE THE DURATION OF NEUTRALIZING ANTIBODIES IN CATTLE VACCINATED WITH INACTIVATED FMD VACCINE

* M.R.YOUSEF

* FMD Dept., Vet. Serum and Vaccine Research Institute, Abbasia, Cairo, Egypt,

Postal code 11381.

Received: 13.9.2004.

Accepted: 16.12.2004.

SUMMARY

Inactivated FMD vaccine is weakly immunogenic and multiple vaccinations at four-month intervals are necessary for the prevention of the disease. Our results revealed that in cyclophosphamide treated animals, the antibody titers remained protecting up to 35 weeks post vaccination ,while in non treated group, the animals became susceptible to infection 19 weeks post vaccination. So, it is possible to increase the duration of neutralizing antibodies in serum when a low single dose of cyclophosphamide is administered four days before vaccination with aluminum hydroxide-saponin FMD vaccine and this will increase the intervals between vaccinations and decrease the commercialization costs of vaccination programmes.

INTRODUCTION

Foot and mouth disease is a highly contagious disease that affects both domestic and wild cloven-hoofed animals leading to the appearance of vesicles on the feet, in the oral cavity, and on the mammary glands of females. Mortality from myocarditis is most commonly seen in young animals and healing of vesicular lesions usually takes place in 2-3 weeks (Ivonne et al., 1995). It is caused by seven types of foot and mouth disease virus (FMDV) in the genus Aphthovirus; family Picornaviridae, with at least 70 subtypes (Davies 2002).

Vaccination constitutes an important control policy for foot and mouth disease in affected areas with advanced eradication programs, as well as, in free regions that decide to use immunization as

control measure after recent introduction of the disease (Bergmann et al., 2003).

The immunity acquired through infection or use of current vaccine is strictly type specific and to a lesser degree, subtype-specific (Frederic et al., 1999).

Inactivated FMD vaccine is poorly immunogenic (Doel, 1999) and multiple vaccinations at six-month intervals are necessary for the prevention of the disease. Usually, cattle receive two to eight vaccine inoculations before slaughter and this will increase the cost of repeated vaccination. (Portiansky et al., 1996).

In addition to the high costs of the repeated vaccination, the oil adjuvant can be harmful and frequent appearance of subcutaneous abscesses will decrease the economic value of cattle (Fondevila et al., 1993).

There are several trials to increase the level of immune status of farm animals vaccinated against FMDV by using immunomodulators.

When cyclophosphamide, a well-known antimitotic drug, is administered in a very low dose and before antigenic challenge, it can display an immunomodulating activity and enhancing antibody synthesis probably by its action on the suppressor cascade (Dray and Mokyr 1984). If a low dose of cyclophosphamide used before antigenic challenge, it can be a potent immune enhancer

and this augmentation has been attributed to a greater toxicity for suppressor T cells than T helper lymphocytes (Daniel et al., 1997).

The purpose of this work is to study the effect of cyclophosphamide on the life span of neutralizing antibodies in the serum of cattle vaccinated with inactivated aqueous FMD vaccine.

MATERIALS AND METHODS

1. Cyclophosphamide: $C_7H_{15}Cl_2N_2O_2P.H_2O$ F.W. 279.1., Cat. No. C-0768 lot. 091k1176 Sigma - Aldrich CO., USA.

A well known antimitotic drug and characterized by its rapid clearance from the blood due to its short half-life time (2-4 hours) (Kawabata et al., 1990)

2- Calves: Two groups (each contained three calves) of 6-8 month old with 200-300Kg body weight were used. These calves were clinically healthy and free from antibodies against FMD virus as proved by using SNT and ELISA.

3- Virus: The virus used in this study was the locally isolated FMD virus type O₂/1993. Viral stock of O₂ was prepared by infecting BHK₂₁ cell monolayer. Virus particles were collected from the supernatant and cleared by centrifugation (3000 rpm). The cytopathic effect of FMDV on BHK₂₁ cells 24 hours after infection was determined by TCID₅₀ of (Reed and Muench-1938) analysis. Viral stock were maintained at -70°C.

4- Baby hamster kidney cells (BHK₂₁ clone 13): The cells were propagated at FMD department, Abbasia, Cairo, using Minimum Essential Medium (MEM) with Earls salts with 8-10% sterile newborn calf serum.

5- FMD vaccine: FMD virus type O₁/93 was inactivated by binary ethylenimine and adjuvanted by aluminum hydroxide, batch no.12/2003, each dose contains 3 cattle PD50 and was produced at Veterinary Serum and Vaccine Research Institute, FMD Department, Abbasia, Cairo, Egypt.

6- Serum neutralization test (SNT):

It was performed using the microtechnique described by (Ferreira 1976) in which serial dilutions of the sera, in triplicate, were mixed with 10⁴ TCID₅₀. The neutralization titer of the tested sera was obtained according to the (Reed and Muench 1938).

7- Enzyme linked immunosorbent assay (ELISA):

It was carried out according to the method described by (Hamblin et al., 1986).

EXPERIMENTAL DESIGN

Two groups of calves (each contained three animals) were used in the experiment. Four days before vaccination, a group of calves received cyclophosphamide (5 mg/Kg body weight dissolved in 5 ml of double distilled water) by intraperitoneal route. Both groups were immunized with FMD vaccine by a subcutaneous route. Serum samples were collected weekly till 5 weeks then every 2 weeks post vaccination. The immune response was evaluated using SNT and ELISA techniques.

RESULTS

Table 1: Comparative serum neutralizing antibody titers of cattle treated with cyclophosphamide before vaccination and non treated gorup.

weeks post vaccination	cy-treated group **				non treated group **			
	cattle no.			Mean	cattle no.			Mean
	1	2	3		4	5	6	
Prevaccination	0.3*	0.5	0.4	0.4	0.3	0.6	0.4	0.4
1	0.9	1.0	0.8	0.9	0.9	0.9	0.8	0.9
2	1.4	1.5	1.3	1.4	1.4	1.2	1.3	1.3
3	1.5	1.9	1.7	1.7	1.7	1.5	1.5	1.6
4	1.75	2.25	2.0	2.0	2.0	1.8	1.6	1.8
5	2.1	2.7	2.0	2.25	2.3	2.1	2.1	2.2
7	2.0	2.4	2.3	2.2	2.4	2.1	2.1	2.25
9	1.9	2.1	2.0	2.0	2.2	1.9	1.9	2.0
11	1.85	2.1	2.0	2.0	2.0	1.7	1.6	1.8
13	1.7	1.9	1.9	1.8	2.0	1.5	1.6	1.7
15	1.7	1.8	1.7	1.7	1.8	1.3	1.5	1.5
17	1.6	1.75	1.7	1.7	1.75	1.3	1.2	1.4
19	1.6	1.75	1.7	1.7	1.75	1.0	0.8	1.2
21	1.4	1.6	1.5	1.5	1.4	0.7	0.6	0.9
23	1.3	1.5	1.4	1.4	1.0	0.5	0.5	0.7
25	1.3	1.4	1.4	1.4	0.8	0.4	0.5	0.5
27	1.3	1.3	1.4	1.4				
29	1.2	1.3	1.3	1.25				
31	1.2	1.25	1.3	1.25				
33	1.0	1.25	1.3	1.2				
35	1.0	1.25	1.25	1.2				
37	0.7	1.0	0.9	0.9				
39 weeks	0.6	0.6	0.7	0.6				

* Values expressed in log 10 of the reciprocal of the 50% serum end-point dilution.
 ** Cattle treated with cyclophosphamide four days before vaccination.

Figure (1): Comparative means of serum neutralizing antibody titers of cattle treated with cyclophosphamide before vaccination and non treated group.





Table 2: Comparative ELISA antibody titers of cattle treated with cyclophosphamide before vaccination and non treated group.

weeks post vaccination	cy-treated group **				non treated group **			
	cattle no.			Mean	cattle no.			Mean
	1	2	3		4	5	6	
Prevaccination	0.7*	0.9	0.9	0.8	0.7	0.9	0.7	0.75
1	1.2	1.45	1.2	1.3	1.2	1.3	1.25	1.25
2	1.9	1.9	1.75	1.85	1.8	1.7	1.75	1.75
3	1.9	2.4	2.0	2.1	2.1	1.9	2.0	2.0
4	2.1	2.7	2.45	2.4	2.45	2.25	2.25	2.3
5	2.6	3.1	2.45	2.7	2.75	2.5	2.6	2.6
7	2.35	2.75	2.75	2.6	2.9	2.5	2.8	2.7
9	2.2	2.5	2.45	2.4	2.6	2.25	2.45	2.4
11	2.2	2.5	2.45	2.4	2.45	2.1	2.2	2.25
13	2.0	2.3	2.3	2.2	2.45	1.9	2.1	2.15
15	2.0	2.25	2.1	2.1	2.1	1.75	1.8	1.9
17	2.0	2.2	2.1	2.1	2.0	1.75	1.7	1.8
19	1.9	2.2	2.1	2.1	2.0	1.4	1.65	1.7
21	1.7	2.1	1.9	1.9	1.75	1.2	1.2	1.4
23	1.65	1.85	1.9	1.9	1.45	0.75	0.75	1.0
25	1.65	1.85	1.8	1.9	1.2	0.6	0.75	0.85
27	1.65	1.85	1.8	1.9				
29	1.65	1.7	1.75	1.7				
31	1.65	1.7	1.75	1.7				
33	1.4	1.7	1.75	1.65				
35	1.4	1.7	1.65	1.65				
37	1.2	1.4	1.2	1.3				
39 weeks	1.0	0.9	1.2	1.0				

* Values expressed in log 10 of the reciprocal of the 50% serum end-point dilution.
 ** Cattle treated with cyclophosphamide four days before vaccination.

Figure (2): Comparative means of ELISA antibody tiers of cattle treated with cyclophosphamide before vaccination and non treated group.



DISCUSSION

The immunization of cloven hoofed animals with killed FMD vaccine requires periodic vaccination due to low vaccine immunogenicity. Therefore, FMDV antigens need to be combined with adjuvants such as aluminum hydroxide, saponin or oil emulsion. Animal handling for periodic inoculation and the repeated doses of vaccines increase the commercialization costs. Moreover the use of adjuvants may induce adverse effects (Portiansky et. al., 1996). Therefore the search for increasing the duration of neutralizing antibodies in the serum of cattle vaccinated with inactivated FMD vaccine is justified to decrease the numbers of inoculation and consequently the cost of vaccination .

In table (1) and (2) neutralizing and ELISA antibody titers could be detected as early as 7 days after vaccination then increased rapidly till reached a protective level at 3rd week .These results are agreed with (Kardiasis et. al., 1964), (Wisniewski et. al ., 1972) and (Bengelsdroff , 1989) who found that more than 95% of the vaccinated cattle with SN titers of greater than 1.2 were protected from generalized FMD, 61.5% of vaccinated cattle with SN titers less than or equal 1.2 were not protected and developed generalized infection . At 3rd week post vaccination, no significant difference were found in neutralizing antibody titers against the O1 serotype between the

cyclophosphamide treated and non treated animals. Statistically significant ($p < 0.005$) difference between the two groups were observed after 19 weeks post vaccination. 19 weeks post vaccination the neutralizing antibody titer while in non treated group was reduced almost completely and animals became susceptible to infection, the cyclophosphamide treated animals showed significant higher antibody titers at a level that can protect them from infection with the homologous virus up to 35 weeks post vaccination. These results are agreed with (Portiansky et. al ., 1996) who found that pretreatment with cyclophosphamide increased the duration of anti-FMDV neutralizing antibodies in cattle vaccinated with the commercial aluminium hydroxide-saponin FMD vaccine. Also these results are supported by (Portiansky et .al., 1989) who found that when adult mice were administered with a low dose of cyclophosphamide 4 days before infection with FMDV, viral replication and pancreatic damage can be prevented and the immune response against virus was enhanced.

Also our results are in agreement with (Hamblin et. al., 1986) who found a positive correlation between ELISA and virus neutralization titers for sera either vaccinated or involved in outbreaks of FMDV. The protective level was 1.2 log₁₀ by means of SN test which equivalent to 1.65 log₁₀ by means of ELISA.

CONCLUSION

It is possible to increase the duration of neutralizing antibodies in serum when a single dose of cyclophosphamide is administered four days before vaccination with aluminum hydroxide-saponin FMD vaccine. So increasing the intervals between vaccinations will decrease the commercialization costs of vaccination programs.

REFERENCES

- Bengelsdroff H. J., (1989): Testing the effectiveness of FMD vaccines, the relationship between the infection results and corresponding neutralization titers of vaccinated cattle. *Berl Munch Tierarztl Wochenschr* . Jun : 102-109.
- Bergmann I.E., Malirat V., Neitzert E., Correa Melo E. (2003): Vaccines and companion diagnostic tests for foot and mouth disease virus, an overview of the experience in South America. *Dev Bio (Basel)*. 114:59-65.
- Daniel P. Stites, Abba I. Terr and Tristram G. Parslow (1997): *Medical Immunology*, 830-830, ninth edition, Prentice-Hall International Inc.
- Davies G.; (2002): Foot and Mouth Disease. *Res. Vet. Sci.* Dec; 73(3): 195-199.
- Doel T.R. (1999): Optimization of the immune response to foot and mouth disease vaccines. *Vaccines* 17, 1767-1771.
- Dray , S. and Mokyr , M. B. (1984) : Immunomodulation .*New Frontiers and Advances*, p.349. EDS H,H. Fundenberg, H.D.Whitten and F.Ambrogi. Plenum Press, New York.
- Frederic A., Paul J E., Marian C. and Michael J. (1999): *Veterinary Virology* , third edition , Academic Press.
- Ferreira , M. E. (1976). Prubade micro neutralization proes-tuase de anticurpos de le fiebre aftose.Bltm. Centropan Americano Fieber Aftosa 21/22 :21-25
- Fondevila, N.A., Frick, E., Lopez, A.G., ODonell, V.K., Smittsaart, E.N., MarcoveCchio,F., and Schudel, A.A., (1993): *Vet. Arg.* (10) 26-30, cited from Portiansky E L, Gonzalez P H and Laguens R P (1996)The use of cyclophosphamide as an inhancer of the vaccine against foot and muoth disease .*Experientia* 52; 605-607.
- Hamblin C., Barnett I.T.R., and Crowther J.R., (1986): A new enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against FMD virus. [I Application. *Journal of immunological methods*, 93:123-129. Ivonne L. Archetti, Massimo Amadori, Anna Donn, Jeremy Salt, and Ezio Lodetti (1995): Detection of FMD virus infected cattle by assessment of antibody response in oropharyngeal fluids. *Journal of clinical of clinical microbiology*, Jan.1995, p.79-84.
- Kardiasis I., Papaus C., Brovas D., Karovalakis I., and Seimenis A.(1964): Antibody response in cattle after vaccination against FMDV with a monovalent (O) vaccine in Greece. *Bull. Soc. Vet.Hell.*,14: 94-104.
- Kawabata,TT., Chapman,M,Y., Kim, D. H., Stevens,W.D., and Holsapple, M., P.. (1990): *Biochem. Pharmac.* (40) 927-932. cited from Portiansky E L, Gonzalez P H and Laguens R P (1996) The use of cyclophosphamide as an inhancer of the vaccine against foot and muoth disease . *Experientia* 52; 605-607.
- Portiansky E. L, DiGirolamo W.M.T. and Laguens R. P. (1989): Protective and immunostimulating activity of a low dose of cyclophosphamide in the experimental infec-

tion of mice with foot and mouth disease virus. *Experientia* 45; 110-112.

Portiansky E. L, Gonzalez P. H. and Laguens R. P. (1996): The use of cyclophosphamide as an enhancer of the vaccine against foot and mouth disease . *Experientia* 52; 605-607.

Reed, L.J. and Muench , H. (1938): A simple method of estimating fifty percent end points. *Am. J. Hyg.* 27: 493-497.

Wisniewski , J., Kobusiewicz T., Baronowski C., and Jan-kowsko J., (1972): Determination of the level of immunity in cattle on the basis of neutralizing antibodies after the use of a Frenkel type FMD vaccine. *Medycyna Wet* 28 (10) :586-588.